Régions d'ancrage à la matrice nucléaire : Questions médicales fréquentes
Nom anglais: Matrix Attachment Regions
Descriptor UI:D045170
Tree Number:G05.360.080.534
Termes MeSH sélectionnés :
Predictive Value of Tests
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Régions d'ancrage à la matrice nucléaire : Questions médicales les plus fréquentes",
"headline": "Régions d'ancrage à la matrice nucléaire : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Régions d'ancrage à la matrice nucléaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-10",
"dateModified": "2025-04-06",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Régions d'ancrage à la matrice nucléaire"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Structures génétiques",
"url": "https://questionsmedicales.fr/mesh/D040342",
"about": {
"@type": "MedicalCondition",
"name": "Structures génétiques",
"code": {
"@type": "MedicalCode",
"code": "D040342",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Régions d'ancrage à la matrice nucléaire",
"alternateName": "Matrix Attachment Regions",
"code": {
"@type": "MedicalCode",
"code": "D045170",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Tian-Yun Wang",
"url": "https://questionsmedicales.fr/author/Tian-Yun%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China."
}
},
{
"@type": "Person",
"name": "Xiao-Yin Wang",
"url": "https://questionsmedicales.fr/author/Xiao-Yin%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China."
}
},
{
"@type": "Person",
"name": "Yan-Long Jia",
"url": "https://questionsmedicales.fr/author/Yan-Long%20Jia",
"affiliation": {
"@type": "Organization",
"name": "Pharmacy Collage, Xinxiang Medical University, Xinxiang 453003, Henan, China."
}
},
{
"@type": "Person",
"name": "Xiao Guo",
"url": "https://questionsmedicales.fr/author/Xiao%20Guo",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China; International Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang 453003, Henan, China."
}
},
{
"@type": "Person",
"name": "Lubna Anis",
"url": "https://questionsmedicales.fr/author/Lubna%20Anis",
"affiliation": {
"@type": "Organization",
"name": "Owerko Centre for Children's Neurodevelopment and Mental Health, Alberta Children's Hospital Research Institute, Faculty of Nursing, University of Calgary, Calgary, AB T2N 1N4, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Predictive values of an immunological fecal occult blood test for the diagnosis of colorectal cancer compared using colonoscopy in symptomatic patients in Yaounde (Cameroon).",
"datePublished": "2024-06-14",
"url": "https://questionsmedicales.fr/article/38877426",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12876-024-03292-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Natural frequency tree- versus conditional probability formula-based training for medical students' estimation of screening test predictive values: a randomized controlled trial.",
"datePublished": "2024-10-24",
"url": "https://questionsmedicales.fr/article/39449124",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12909-024-06209-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prognostic value of cardiopulmonary exercise test in children with congenital heart defects.",
"datePublished": "2024-08-19",
"url": "https://questionsmedicales.fr/article/39160087",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/openhrt-2024-002820"
}
},
{
"@type": "ScholarlyArticle",
"name": "The value of multiparameter combinations for predicting difficult airways by ultrasound.",
"datePublished": "2022-10-05",
"url": "https://questionsmedicales.fr/article/36199026",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12871-022-01840-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Advanced serrated polyps as a target of screening: detection rate and positive predictive value within a fecal immunochemical test-based colorectal cancer screening population.",
"datePublished": "2022-11-02",
"url": "https://questionsmedicales.fr/article/36323332",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/a-1971-3488"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Régions d'ancrage à la matrice nucléaire",
"item": "https://questionsmedicales.fr/mesh/D045170"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Régions d'ancrage à la matrice nucléaire - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Régions d'ancrage à la matrice nucléaire",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Régions d'ancrage à la matrice nucléaire",
"description": "Comment identifier les MAR dans le génome ?\nQuels tests sont utilisés pour étudier les MAR ?\nLes MAR sont-elles visibles par microscopie ?\nPeut-on détecter des mutations dans les MAR ?\nLes MAR sont-elles associées à des maladies ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Predictive+Value+of+Tests&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Régions d'ancrage à la matrice nucléaire",
"description": "Quels symptômes sont liés aux anomalies des MAR ?\nLes MAR affectent-elles l'expression génique ?\nY a-t-il des symptômes associés aux cancers liés aux MAR ?\nLes MAR influencent-elles le développement embryonnaire ?\nLes anomalies des MAR peuvent-elles causer des troubles ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Predictive+Value+of+Tests&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Régions d'ancrage à la matrice nucléaire",
"description": "Peut-on prévenir les anomalies des MAR ?\nY a-t-il des tests de dépistage pour les anomalies des MAR ?\nComment réduire le risque de cancers liés aux MAR ?\nL'alimentation influence-t-elle les MAR ?\nLes examens médicaux réguliers aident-ils ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Predictive+Value+of+Tests&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Régions d'ancrage à la matrice nucléaire",
"description": "Y a-t-il des traitements ciblant les MAR ?\nComment les thérapies géniques affectent-elles les MAR ?\nLes traitements du cancer affectent-ils les MAR ?\nPeut-on utiliser des médicaments pour moduler les MAR ?\nLes interventions chirurgicales peuvent-elles affecter les MAR ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Predictive+Value+of+Tests&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Régions d'ancrage à la matrice nucléaire",
"description": "Quelles complications peuvent survenir avec des anomalies des MAR ?\nLes anomalies des MAR peuvent-elles entraîner des maladies chroniques ?\nY a-t-il des complications liées aux traitements des MAR ?\nLes complications sont-elles réversibles ?\nLes anomalies des MAR affectent-elles la fertilité ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Predictive+Value+of+Tests&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Régions d'ancrage à la matrice nucléaire",
"description": "Quels sont les facteurs de risque pour les anomalies des MAR ?\nL'âge influence-t-il les anomalies des MAR ?\nLe mode de vie affecte-t-il les MAR ?\nLes antécédents familiaux jouent-ils un rôle ?\nLes agents environnementaux influencent-ils les MAR ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Predictive+Value+of+Tests&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les MAR dans le génome ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les MAR peuvent être identifiées par des techniques de séquençage et d'analyse bioinformatique."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour étudier les MAR ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme la PCR et l'hybridation in situ sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les MAR sont-elles visibles par microscopie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les MAR ne sont pas directement visibles, mais leur effet sur la structure peut l'être."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des mutations dans les MAR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations dans les MAR peuvent être détectées par séquençage ciblé."
}
},
{
"@type": "Question",
"name": "Les MAR sont-elles associées à des maladies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines MAR peuvent être liées à des maladies génétiques ou à des cancers."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux anomalies des MAR ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anomalies des MAR peuvent entraîner des dysfonctionnements cellulaires, mais pas de symptômes spécifiques."
}
},
{
"@type": "Question",
"name": "Les MAR affectent-elles l'expression génique ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les MAR jouent un rôle crucial dans la régulation de l'expression génique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes associés aux cancers liés aux MAR ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes dépendent du type de cancer, mais peuvent inclure fatigue, douleur, et perte de poids."
}
},
{
"@type": "Question",
"name": "Les MAR influencent-elles le développement embryonnaire ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les MAR sont impliquées dans la régulation des gènes essentiels au développement embryonnaire."
}
},
{
"@type": "Question",
"name": "Les anomalies des MAR peuvent-elles causer des troubles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies peuvent contribuer à des troubles du développement ou des cancers."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies des MAR ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques de maladies associées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests de dépistage pour les anomalies des MAR ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de tests de dépistage spécifiques pour les anomalies des MAR."
}
},
{
"@type": "Question",
"name": "Comment réduire le risque de cancers liés aux MAR ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les facteurs de risque connus comme le tabagisme et l'exposition à des agents cancérigènes."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle les MAR ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut influencer l'expression génique, y compris celle des MAR."
}
},
{
"@type": "Question",
"name": "Les examens médicaux réguliers aident-ils ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent aider à détecter précocement des maladies associées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements ciblant les MAR ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de traitements spécifiques ciblant les MAR."
}
},
{
"@type": "Question",
"name": "Comment les thérapies géniques affectent-elles les MAR ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les thérapies géniques peuvent modifier l'expression des gènes associés aux MAR."
}
},
{
"@type": "Question",
"name": "Les traitements du cancer affectent-ils les MAR ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements du cancer peuvent influencer l'activité des MAR."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des médicaments pour moduler les MAR ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours pour développer des médicaments modulant l'activité des MAR."
}
},
{
"@type": "Question",
"name": "Les interventions chirurgicales peuvent-elles affecter les MAR ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Indirectement, en modifiant l'environnement cellulaire, mais pas directement les MAR."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des anomalies des MAR ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles du développement et un risque accru de cancers."
}
},
{
"@type": "Question",
"name": "Les anomalies des MAR peuvent-elles entraîner des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines anomalies peuvent contribuer à des maladies chroniques comme le cancer."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications liées aux traitements des MAR ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent avoir des effets secondaires, mais pas spécifiquement liés aux MAR."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Les anomalies des MAR affectent-elles la fertilité ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines anomalies peuvent influencer la fertilité, mais cela dépend du contexte génétique."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies des MAR ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des prédispositions génétiques et des expositions environnementales."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les anomalies des MAR ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge avancé peut augmenter le risque de mutations génétiques, y compris dans les MAR."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il les MAR ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme le tabagisme et l'alimentation peuvent influencer les MAR."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies génétiques peuvent augmenter le risque d'anomalies."
}
},
{
"@type": "Question",
"name": "Les agents environnementaux influencent-ils les MAR ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des agents cancérigènes peut affecter l'intégrité des MAR."
}
}
]
}
]
}
The predictive value of immunological fecal occult blood (iFOB) testing for the screening of colorectal cancer has been well described in the Western world. However, its relevance in Sub-Saharan Afric...
We conducted an analytical cross-sectional study in two digestive endoscopic centers of Yaoundé (Cameroon) from the 1...
We included 103 patients during the study period with a male predominance and a sex ratio of 1.7. The median age [IQR] was 52 [38-65] years (range 1 - 84 years). The most common colonoscopic lesions w...
The iFOB test has a good NPV, but a poor PPV for the diagnosis of CRC in our study....
Medical students and professionals often struggle to understand medical test results, which can lead to poor medical decisions. Natural frequency tree-based training (NF-TT) has been suggested to help...
We conducted a parallel group randomized controlled trial of NF-TT vs. CP-FT in two medical schools in South Korea (a 1:1 allocation ratio). Participants were randomly assigned to watch either NF-TT o...
Overall, NF-TT was not more effective than CP-FT in improving the predictive value estimation accuracy at post-intervention (NF-TT: 87.13%, CP-FT: 86.03%, p = .86) and follow-up (NF-TT: 72.39%, CP-FT:...
Introducing NF-TT early in the medical school curriculum, before students are exposed to a pervasive conditional probability formula-based approach, would offer the greatest benefit....
Korea Disease Control and Prevention Agency Clinical Research Information Service KCT0004246 (the date of first trial registration: 27/08/2019). The full trial protocol can be accessed at https://cris...
Cardiopulmonary exercise testing (CPET) has an important prognostic value in adults with different congenital heart defects (CHDs) and is a useful tool for risk stratification and clinical decision-ma...
411 CPET performed by paediatric patients with different CHDs were evaluated in this retrospective study. Medical records were reviewed to determine the presence of cardiac events. Participants were c...
411 patients with a median age at test of 12 years, 51 patients with simple CHD, 170 patients with moderate complexity CHD and 190 with high complexity CHD underwent CPET. Overall, CPET parameters wer...
Reduced exercise capacity at young age is related to a higher probability of future cardiovascular events in paediatric patients with CHD. Submaximal exercise variables can be used instead when maxima...
Based on the upper airway anatomy and joint function parameters examined by ultrasound, a multiparameter ultrasound model for difficult airway assessment (ultrasound model) was established, and we eva...
A prospective case-cohort study of difficult airway prediction in adult patients undergoing elective surgery with endotracheal intubation under general anesthesia, and ultrasound phantom examination f...
We successfully enrolled 1000 patients, including 51 with difficult laryngoscopy (DL) and 26 with difficult tracheal intubation (DTI). The area under the ROC curve (AUC) for the ultrasound model to pr...
The ultrasound model has good predictive performance for difficult airways....
This study is registered on chictr.org.cn (ChiCTR-ROC-17013258); principal investigator: Jianling Xu; registration date: 06/11/2017)....
BACKGROUND : Advanced serrated polyps (ASPs) have a comparable risk to advanced adenomas for progression to colorectal cancer (CRC). The yield of most CRC screening programs, however, is based on adva...
To determine if the sensitivity of the lateral flow test is dependent on the viral load and on the location of swabbing in the respiratory tract in children....
Phase 1: Routinely performed reverse transcriptase PCR (RT-PCR) using nose and throat (NT) swabs or endotracheal (ET) aspirates were compared with Innova lateral flow tests (LFTs) using anterior nasal...
Tertiary paediatric hospitals....
Children under the age of 18 years. Phase 1: undergoing routine testing, phase 2: known SARS-CoV-2 positive....
Phase 1: 435 paired swabs taken in 431 asymptomatic patients resulted in 8 positive RT-PCRs, 9 PCR test failures and 418 negative RT-PCRs from NT or ET swabs. The test performance of AN LFT demonstrat...
The NPV, PPV and specificity of LFTs are excellent. The sensitivity of LFTs compared with RT-PCR is good when the samples are colocated but may be reduced when the LFT swab is taken from the AN. Bucca...
NCT04629157....
New-onset atrial fibrillation (NOAF) is a common adverse outcome in acute ST-segment elevation myocardial infarction (STEMI) patients following percutaneous coronary intervention (PCI) and is associat...
445 elderly STEMI patients without a history of atrial fibrillation (AF) who underwent PCI were consecutively enrolled in this study. Multivariate logistic regression analysis was used to identify ind...
50 patients (11.2%) developed NOAF after PCI. Multivariate logistic regression analysis revealed that heart rate (HR), systemic immune-inflammation index (SII), uric acid (UA), PAR, and C...
The combination of PAR and the C...
Identifying patients presenting with nonspecific abdominal symptoms who have underlying cancer is a challenge. Common blood tests are widely used to investigate these symptoms in primary care, but the...
Using data from the UK Clinical Practice Research Datalink (CPRD) linked to the National Cancer Registry, Hospital Episode Statistics and Index of Multiple Deprivation, we conducted a population-based...
In patients consulting with nonspecific abdominal symptoms, the assessment of cancer risk based on symptoms, age and sex alone can be substantially enhanced by considering additional information from ...
To determine the positive predictive value (PPV) of a sepsis-screening protocol in patients with cervical spinal cord injury (SCI)....
Retrospective review of all patients with cervical SCI who screened positive for two or more systemic inflammatory response syndrome (SIRS) criteria while hospitalized in acute care or inpatient rehab...
A total of 134 patients screened positive for two or more SIRS criteria. Of these, 36 patients (26.9%) were diagnosed with sepsis. Factors associated with a true-positive SIRS screen on multivariable ...
Sepsis screening using SIRS criteria in hospitalized patients with tetraplegia has a PPV of 26.9%; it is significantly higher in patients with AIS A-C versus D injuries. AMS, when combined with a posi...
Exploring the predictive value of NLR, PLR, MLR, and SII for the severity of cervical cancer screening abnormalities in patients....
A retrospective analysis was conducted on the data of 324 patients suspected of cervical lesions due to abnormal TCT and/or HPV in our hospital from January 2023 to December 2023, who underwent colpos...
The levels of NLR, PLR, and SII in the group without cervical lesions were lower than those in the group with cervical lesions (p < 0.05), and there was no statistically significant difference in MLR ...
Although the peripheral blood NLR, PLR, and SII of the cervical lesions patients were higher than those without cervical lesions in cervical cancer screening abnormal patients, the predictive ROC curv...